Highlights from 2024 World Conference on Lung Cancer

ByJessica Jones

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 World Conference on Lung Cancer, as well as Healio’s top headlines from the meeting.

Benjamin P. Levy, MD, discusses key takeaways from the meeting. 0:28

Read the full coverage here:

Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard’

Source: Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

Perioperative nivolumab improves outcomes in resectable NSCLC

Source: Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

Despite progress, barriers to lung cancer biomarker testing persist

Source: Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

Published by:

Sources/Disclosures

Collapse

Disclosures: Healio could not confirm relevant financial disclosures for Levy at the time of posting.

Read more

Highlights from 2024 World Conference on Lung Cancer

Meeting Mic: World Conference on Lung Cancer

Related Content